Where other compounds fit The broader competitive landscape includes several emerging triple agonists and next-generation compounds
For patients currently using licensed injectable GLP-1 receptor agonists in the UK: Once-daily formulations include liraglutide (Victoza) [2] Once-weekly formulations include semaglutide (Ozempic), dulaglutide (Trulicity), and exenatide extended-release (Bydureon) [1] [2] If you are participating in a clinical trial involving a GLP-1 patch, you must strictly follow the specific instructions provided by the research team regarding application duration, replacement schedule, and all other aspects of use
Collective Impact: The participant group achieved a cumulative weight loss of 2,732 kg
GLP-1 medications have demonstrated cardioprotective effects in type 2 diabetes, and while data in type 1 diabetes are limited, the potential is promising
Understanding the distinction between expected injection reactions and potentially concerning signs helps patients make appropriate decisions about seeking care
At Rejuvime, your provider monitors your progress and may adjust your dose or pacing to help manage side effects safely
